Press Room

Article / Nov 10, 2017

Learning From History: For CMOs the Cycle is Back

Guy Villax, November 10, 2017

What is happening to the CMO industry (particularly the pharmaceutical fine chemical industry) looks pretty similar to what it did almost 20 years ago.听The attached 13 articles written between 1998 and 2005 -half of which were written by me- recount a well-known story:听exuberance and over-investment results in write-offs and losses.听What happened then was crystal clear to me when in 1998 someone came with a large cheque book convinced that a $500m API business could be built in 3-5 years.听Shortly thereafter a well-known Deutsche Bank analyst鈥檚 report made sure the herd mentality took over.听By 2005 most of the $15bn or so spent in M&A deals were mostly written off and a number of wonderful brands and several major companies had vanished.

It is interesting to note that at the time that some entered the CMO business Honeywell was exiting and said:听鈥...pharmaceutical chemical manufacture is a highly capital intensive business plagued by over-capacity,听clinical trial failures, limited new drug approvals, new drug marketing disappointments, and price wars鈥︹澨

Maybe there is an opportunity to learn from history.听The challenge today is to check whether what looks the same is indeed the same, and whether what is really different can contribute to a different outcome.听What remains to be seen is whether outsiders understand what they are getting into, and one thing is certain: when the dust settles you will have the usual suspects picking up the pieces.

If anything we should be concerned because as of today over $33bn have already been spent in CMO related M&A activity in the last 4 years 鈥 in exactly the same pattern as in 1995-7, 1998-2000.

Yours,
Guy

# 罢颈迟濒别听 Type Author Date
1 The API Solution Provider article Guy Villax 1998
2 Aggressive goals - $500m in 3-5 years ppt Solutia 1998
3 Deutsche Bank analyst's report on CMO article DB 1999
4 四色AV in the CPHI show daily 2001 article Guy Villax 2001
5 Pharma Fine Chemicals - Nothing has changed! article Guy Villax 2002
6 Outsourcing: The dust has now settled听 article Guy Villax 2002
7 European producers face unique issues article Maureen Rouhi 2005
8 Why Fine Chemical Business Development has failed听 ppt Peter Pollak 2005
9 GMP fraud - largest ever penalties in criminal pharma听 web 2005
10 Clients, competitors and Consultants听 ppt Guy Villax 2005
11 Fine Chemicals Revisited听 article Guy Villax 2005
12 5 years after its buying spree鈥 article Clay Boswell 2005
13 The Gold Sheet听 article听 Bill Paulson听 2006

View the full set of documents听(PDF, 8MB)

Guy Villax
四色AV
+351 917 888 899

Also in the Press Room

See All

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024